It's all in the Timing: Insights into Diabetes Treatment
On June 27, 2014, the US Food and Drug Administration approved Afrezza (insulin human) Inhalation Powder to improve glycemic control in adults with diabetes mellitus. Afrezza is a dry powder formulation of insulin for oral inhalation. The insulin in Afrezza is both rapidly absorbed from the lungs into the system circulation and rapidly cleared, producing a quick onset and short duration of actions. This profile is distinct from other current insulin therpaies and provides the potential to reduce the risk of hypoglycemia. The effect of a more rapid onset and shorter duration of activity will be illustrated through modeling of the pharmacokinetics (PK) and pharmacodynamics (PD) of insuklin, and clinical data relating the timing and extent of hypoglycemia will also be presented. The physicochemical characteristics of the drug powder and their relationship to pulmonary drug delivery will also be prevented.